PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies

B Lenormand; M C Béné; J F Lesesve; C Bastard; H Tilly; M P Lefranc; G C Faure; R Garand; A Falkenrodt; G Kandel; E Solary; M Maynadié; M P Callat; F Thouret; M Monconduit; J P Vannier

doi:10.3109/10428199809092688

PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies

Leuk Lymphoma. 1998 Jan;28(3-4):329-42. doi: 10.3109/10428199809092688.

Authors

B Lenormand¹, M C Béné, J F Lesesve, C Bastard, H Tilly, M P Lefranc, G C Faure, R Garand, A Falkenrodt, G Kandel, E Solary, M Maynadié, M P Callat, F Thouret, M Monconduit, J P Vannier

Affiliation

¹ Laboratoire Hématologie et Service de Pédiatrie, C.H.U. Charles Nicolle, Rouen, France.

PMID: 9517504
DOI: 10.3109/10428199809092688

Abstract

The less differentiated stage (CD10-) of B-lineage acute lymphoblastic leukaemia (ALL) described as preB1-ALL in the GEIL nomenclature, accounts for less than 10% of ALL. It is classically considered to be associated with translocation (4;11)(q21;q23), and to have a poor prognosis. We report an extensive immunophenotypic, genomic and clinical study of a series of 64 preB-1 ALL patients, representing 6.3% of a cohort of consecutive ALLs. The engagement of preB1-ALL cells in the B-lineage was confirmed by their B-lineage score, equal to or higher than 2. In addition, more than 90% of the cases tested showed rearranged IGH genes. Translocation (4;11) was the most frequent karyotypic anomaly seen, but only accounted for 24% of the preB1-ALL cases tested. Expression of the myeloid associated antigen CD15 was also found with high incidence in this subset. Clinical and biological features at presentation showed more significant differences between preB1- and T-ALL than between preB1- and preB2-ALL (CD10+). However, outcome characteristics of the 22 children with preB1-ALL confirmed the worse prognosis of this entity.

Publication types

Clinical Trial
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Anthracyclines / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Asparaginase / therapeutic use
Burkitt Lymphoma / drug therapy
Burkitt Lymphoma / genetics*
Burkitt Lymphoma / immunology*
Child
Child, Preschool
Cortisone / therapeutic use
Cyclophosphamide / therapeutic use
Daunorubicin / analogs & derivatives
Daunorubicin / therapeutic use
Female
Gene Rearrangement, T-Lymphocyte
Humans
Immunoglobulin Heavy Chains / genetics
Immunophenotyping
Infant
Leukemia-Lymphoma, Adult T-Cell / drug therapy
Leukemia-Lymphoma, Adult T-Cell / genetics
Leukemia-Lymphoma, Adult T-Cell / immunology
Male
Methotrexate / therapeutic use
Neprilysin / analysis
Outcome Assessment, Health Care
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology*
Prednisone / therapeutic use
Prognosis
Steroids / therapeutic use
Vincristine / therapeutic use

Substances

Anthracyclines
Immunoglobulin Heavy Chains
Steroids
Vincristine
Cyclophosphamide
Neprilysin
Asparaginase
Cortisone
Prednisone
Methotrexate
Daunorubicin

Supplementary concepts

FRALLE 93 protocol
LALA 87 protocol
PVDA protocol